Dr. May on Olaratumab Activity in Pediatric Bone and Soft Tissue Sarcoma

Video

Caitlin May, PhD, postdoctoral research fellowship at Eli Lilly and Company, discusses olaratumab's (Lartruvo) demonstrating anti-tumor activity in models of pediatric bone and soft-tissue sarcoma.

Caitlin May, PhD, postdoctoral research fellowship at Eli Lilly and Company, discusses olaratumab's (Lartruvo) demonstrating anti-tumor activity in models of pediatric bone and soft-tissue sarcoma.

In the patient and cell derived xenograft models, olaratumab is seeing the most activity in osteosarcoma and rhabdoid tumor, explains May. When combined with cisplatin, there is an enhancement of activity, but more research must be done.

According to May, oncologists are still trying to better understand the mechanism of action and why olaratumab is advantageous in the preclinical setting. The next step for researchers is going to be looking at different models and the genetic landscape.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD